Lymphoma, B-Cell Clinical Trial
Official title:
Spanish Academy of Dermatology and Venereology (AEDV) Registry of Primary Cutaneous Lymphoma
Registry of patients with Primary Cutaneous Lymphoma seen at participating centers in Spain. The registry will identify patients with this disease and includes information about stage, diagnostic and therapeutic interventions and willingness to participate in further studies.
Status | Recruiting |
Enrollment | 2000 |
Est. completion date | January 1, 2025 |
Est. primary completion date | January 1, 2025 |
Accepts healthy volunteers | No |
Gender | All |
Age group | N/A and older |
Eligibility | Inclusion Criteria: - All consecutive patients with primary cutaneous lymphoma Exclusion Criteria: - Not willing to participate |
Country | Name | City | State |
---|---|---|---|
Spain | Hospital Clinic | Barcelona | |
Spain | Hospital Universitario Basurto | Bilbao | |
Spain | Hospital General de Ciudad Real | Ciudad Real | |
Spain | hospital Universitari de Bellvitge | L'Hospitalet De Llobregat | |
Spain | C.H.U. Insular-Materno Infantil | Las Palmas De Gran Canaria | |
Spain | H.U. Fundación Jiménez Díaz | Madrid | |
Spain | Hospital 12 de Octubre | Madrid | |
Spain | Hospital Universitario Príncipe de Asturias | Madrid | |
Spain | Complejo Hospitalario de Navarra | Pamplona | |
Spain | CHOP-Hospital de Montecelo | Pontevedra | |
Spain | H.U. Nuestra Señora de la Candelaria | Santa Cruz De Tenerife | |
Spain | H.U. Virgen del Rocío | Sevilla | |
Spain | Hospital General Universitario de Valencia | Valencia | |
Spain | Hospital Valencia-Clínico Malva-Rosa | Valencia |
Lead Sponsor | Collaborator |
---|---|
Fundación Academia Española de Dermatología |
Spain,
Peñate Y, Servitje O, Machan S, Fernández-de-Misa R, Estrach MT, Acebo E, Mitxelena J, Ramón MD, Flórez A, Blanes M, Morillo M, Medina S, Bassas J, Zayas A, Espinosa P, Pérez A, Gónzalez-Romero N, Domínguez JD, Muniesa C, López Robles J, Combalia A, Yanguas I, Suh H, Polo-Rodríguez I, Bielsa I, Mateu A, Ferrer B, Descalzo MA, García-Doval I, Ortiz-Romero PL. The First Year of the AEVD Primary Cutaneous Lymphoma Registry. Actas Dermosifiliogr (Engl Ed). 2018 Sep;109(7):610-616. doi: 10.1016/j.ad.2018.03.006. Epub 2018 Apr 19. English, Spanish. — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Maximum TNM stage | Proportion | Through study completion, an average every 1 year | |
Primary | Therapeutic groups used | Including drugs, phototherapy, radiotherapy and procedures (blood marrow transplant) | Through study completion, an average every 1 year | |
Primary | Mortality | Rate | Through study completion, an average every 1 year |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05540340 -
A Study of Melphalan in People With Lymphoma Getting an Autologous Hematopoietic Cell Transplant
|
Phase 1 | |
Completed |
NCT03415399 -
Clinical Study of ET190L1 ARTEMIS™ in Relapsed, Refractory B Cell Lymphoma
|
Phase 1 | |
Withdrawn |
NCT03605589 -
Pembro + Blina Combination in Pediatric and Young Adult Patients With Relapsed/Refractory Acute Leukemia or Lymphoma
|
Phase 1 | |
Recruiting |
NCT04807881 -
Phase Ib Clinical Study of Keynatinib
|
Phase 1 | |
Completed |
NCT05510596 -
Magnetic Resonance Imaging in Immune Effector Cell-Associated Neurotoxicity Syndrome
|
N/A | |
Not yet recruiting |
NCT06350994 -
Early Assessment of Cardiac Function After Treatment With CAR-T Cells
|
||
Terminated |
NCT02670317 -
Phase II Study About Combination CHOP-21, Obinutuzumab and Ibrutinib in Untreated Young High Risk DLBCL Patients.
|
Phase 2 | |
Completed |
NCT00998946 -
Study of Pralatrexate to Treat Participants With Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma
|
Phase 2 | |
Terminated |
NCT00768339 -
A Phase 1-2, Multicenter, Open-Label Study of AEG35156 in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia and Indolent B-Cell Lymphomas
|
Phase 1/Phase 2 | |
Withdrawn |
NCT00538096 -
A Phase I Study to Evaluate Safety, Tolerability in Adults With Lymphoma
|
Phase 1 | |
Terminated |
NCT00521638 -
Study Evaluating TRU-015 in B-Cell Non-Hodgkin's Lymphoma
|
Phase 1 | |
Completed |
NCT00379574 -
Bortezomib Plus CHOP Every 2 Weeks for Advanced Stage DLBCL
|
Phase 1/Phase 2 | |
Completed |
NCT00156013 -
Clofarabine for Relapsed or Refractory T-Cell or B-Cell Non-Hodgkin Lymphoma (NHL)
|
Phase 1/Phase 2 | |
Completed |
NCT00147121 -
Rituximab+Standard CHOP vs Rituximab+Bi-weekly CHOP for Untreated Stage III/IV Low-grade B-cell Lymphoma (JCOG0203)
|
Phase 2/Phase 3 | |
Recruiting |
NCT04594798 -
A Study of Polatuzumab Vedotin, Rituximab and Dose Attenuated CHP in Older Patients With DLBCL
|
Phase 2 | |
Recruiting |
NCT04161248 -
Phase I Master Protocol of Novel Combination Therapy for Patients With Relapsed or Refractory Aggressive B-Cell Lymphoma
|
Early Phase 1 | |
Withdrawn |
NCT04052061 -
QUILT-3.061: CD19 t-haNK in Subjects With Diffuse Large B-Cell Lymphoma
|
Phase 1 | |
Recruiting |
NCT04884035 -
Study of Safety and Efficacy of Iberdomide (CC-220) and CC-99282 Combined With R-CHOP to Treat Lymphoma
|
Phase 1 | |
Not yet recruiting |
NCT05834426 -
Omic Technologies Applied to the Study of B-cell Lymphoma for the Discovery of Diagnostic and Prognosis Biomarkers
|
||
Recruiting |
NCT05376709 -
A Mixed Methods Study of Nutrition Practice in Cancer Care on Non-Hodgkin Lymphoma Population
|
N/A |